Skip to main content
SpringerLink
Log in

Different trends of transmitted HIV-1 drug resistance in Madrid, Spain, among risk groups in the last decade

Archives of Virology volume 159, pages 1079–1087 (2014)Cite this article

Abstract

The presence of transmitted HIV drug resistance (TDR) threatens the efficacy of antiretroviral treatment. We aimed to assess the changes in TDR prevalence over the last decade in Madrid, Spain, to verify the role of the patients’ risk groups in these changes. We analysed the trends of TDR between 2000 and 2011 in a cohort of 1,022 naïve HIV-infected patients in Madrid, Spain, whose pol sequences were available. They included, among others, 369 heterosexuals, 340 men who have sex with men (MSM), and 90 injection drug users (IDUs). TDR was reported following the WHO mutation list. The TDR rate in the whole cohort was 8.3 %, being the highest in MSM (9.1 %) and the lowest in IDUs (4.4 %). Over time, this rate decreased significantly (to 5.4 % in 2009-2011) since the period 2004-2006, when it peaked (10.7 %). Heterosexuals and IDUs showed similar trends, but in the 2009-2011 period, the TDR rate among MSM rebounded to 9.0 % (being absent among IDUs). TDR stabilized in the last years (2007-2011) for nucleoside reverse transcriptase inhibitors. The risk group also determined differences in the mutational profile, sex distribution, proportion of immigrants, and viral variants. In conclusion, the risk group caused different HIV sub-epidemics, determined by the patients’ profiles. Despite the general decreasing trend in TDR, we observed a non-significant increase in TDR rate among MSM, a tendency that needs confirmation. Periodic TDR surveillance is important to prevent the widespread distribution of resistance, especially in MSM, given the growing HIV/AIDS epidemic in this high-risk population.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Sousa JD, Alvarez C, Vandamme AM, Müller V (2012) Enhanced heterosexual transmission hypothesis for the origin of pandemic HIV-1. Viruses 4:1950–1983

    Article  PubMed Central  PubMed  Google Scholar 

  2. UNAIDS (2011) 2010 Report on the global AIDS epidemic http://www.unaids.org/documents/20101123_GlobalReport_em.pdf. Accessed May 28, 2013

  3. SINIVIH (2012) Vigilancia Epidemiológica del VIH/Sida en España: Sistema de Información sobre Nuevos Diagnósticos de VIH y Registro Nacional de Casos de Sida. Secretaría del Plan Nacional sobre el Sida/Centro Nacional de Epidemiología. http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/fd-sida/Informe-VIH-sida-Junio-2012.pdf. Accessed May 28, 2013

  4. Fisher M, Pao D, Brown AE, Sudarshi D, Gill ON, Cane P, Buckton AJ, Parry JV, Johnson AM, Sabin C et al (2010) Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. AIDS 24:1739–1747

    Article  PubMed  Google Scholar 

  5. Hughes GJ, Fearnhill E, Dunn D, Lycett SJ, Rambaut A, Leigh Brown AJ (2009) Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom. PLOS Pathog 5:e1000590

    Article  PubMed Central  PubMed  Google Scholar 

  6. von Wyl V, Kouyos RD, Yerly S, Böni J, Shah C, Bürgisser P, Klimkait T, Weber R, Hirschel B, Cavassini M et al (2011) The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. J Infect Dis 204:1095–1103

    Article  Google Scholar 

  7. González-Alba JM, Holguín Á, García R, García-Bujalance S, Alonso R, Suárez A, Delgado R, Cardeñoso L, González R, García-Bermejo I et al (2011) Molecular surveillance 1 of HIV-1 in Madrid, Spain: a phylogeographic analysis. J Virol 85:10755–10763

    Article  PubMed Central  PubMed  Google Scholar 

  8. Yebra G, Holguín Á, Pillay D, Hué S (2013) Phylogenetic and demographic characterization of HIV-1 transmission in Madrid, Spain. Infect Genet Evol 14:232–239

    Article  PubMed  Google Scholar 

  9. WHO (2012) World Health Organization HIV drug resistance report. http://www.who.int/hiv/pub/drugresistance/report2012/en/index.html. Accessed May 28, 2013

  10. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, Kucherer C, Struck D, Schmit JC, Asjö B et al (2009) Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 200:1503–1508

    Article  PubMed  Google Scholar 

  11. Dolling D, Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, Brown AL, Churchill D, Williams I, Geretti AM et al (2012) Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ 345:e5253

    Article  PubMed  Google Scholar 

  12. Bartmeyer B, Kuecherer C, Houareau C, Werning J, Keeren K, Somogyi S, Kollan C, Jessen H, Dupke S, Hamouda O (2010) Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS One 5:e12718

    Article  PubMed Central  PubMed  Google Scholar 

  13. Colafigli M, Torti C, Trecarichi EM, Albini L, Rosi A, Micheli V, Manca N, Penco G, Bruzzone B, Punzi G et al (2012) Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. Clin Microbiol Infect 18:E299–E304

    Article  CAS  PubMed  Google Scholar 

  14. Frentz D, Boucher CA, van de Vijver DA (2012) Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 14:17–27

    PubMed  Google Scholar 

  15. Monge S, Guillot V, Álvarez M, Peña A, Viciana P, García-Bujalance S, Pérez-Elías MJ, Iribarren JA, Gutiérrez F, Itziar-Casado M et al (2012) Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class. Clin Microbiol Infect 18:E485–E490

    Article  CAS  PubMed  Google Scholar 

  16. Yebra G, de Mulder M, Pérez-Elías MJ, Pérez-Molina JA, Galán JC, Llenas-García J, Moreno S, Holguín Á (2011) Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population. PLoS One 6:e26757

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kucherer C, Obel N, von Wyl V, Masquelier B et al (2011) Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 11:363–371

    Article  PubMed  Google Scholar 

  18. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM et al (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4:e4724

    Article  PubMed Central  PubMed  Google Scholar 

  19. Gifford RJ, Liu TF, Rhee SY, Kiuchi M, Hue S, Pillay D, Shafer RW (2009) The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 25:1197–1198

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Kouyos RD, von Wyl V, Yerly S, Böni J, Rieder P, Joos B, Taffé P, Shah C, Bürgisser P, Klimkait T et al (2011) Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin Infect Dis 52:532–539

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28:2731–2739

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Price MN, Dehal PS, Arkin AP (2010) FastTree 2–approximately maximum-likelihood trees for large alignments. PLoS One 5:e9490

    Article  PubMed Central  PubMed  Google Scholar 

  23. ECDC (2011) European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2010. http://www.euro.who.int/__data/assets/pdf_file/0009/127656/e94500.pdf. Accessed May 28, 2013

  24. Brenner BG, Roger M, Stephens D, Moisi D, Hardy I, Weinberg J, Turgel R, Charest H, Koopman J, Wainberg MA (2011) Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec. J Infect Dis 204:1115–1119

    Article  PubMed Central  PubMed  Google Scholar 

  25. Yerly S, Junier T, Gayet-Ageron A, Amari EB, von Wyl V, Gunthard HF, Hirschel B, Zdobnov E, Kaiser L (2009) The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS 23:1415–1423

    Article  PubMed  Google Scholar 

  26. Hué S, Gifford RJ, Dunn D, Fernhill E, Pillay D (2009) Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol 83:2645–2654

    Article  PubMed Central  PubMed  Google Scholar 

  27. Stadeli KM, Richman DD (2013) Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther 18:115–123

    Article  CAS  PubMed  Google Scholar 

  28. MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, Degenhardt L, Hickman M (2012) Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ 345:e5945

    Article  PubMed Central  PubMed  Google Scholar 

  29. Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C et al (2009) Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 23(6):717–724

    PubMed  Google Scholar 

  30. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, Botes ME, Wellington M, Osibogun A, Sigaloff KC et al (2011) HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 11:750–759

    Article  CAS  PubMed  Google Scholar 

  31. Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Díaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM et al (2011) Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis 203:1174–1181

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Romero A, Sued O, Puig T, Esteve A, Pumarola T, Casabona J, González V, Matas L, Tural C, Rodrigo I et al (2011) Prevalence of transmitted antiretroviral resistance and distribution of HIV-1 subtypes among patients with recent infection in Catalonia (Spain) between 2003 and 2005. Enferm Infecc Microbiol Clin 29:482–489

    Article  PubMed  Google Scholar 

  33. Wainberg MA, Brenner BG (2012) The impact of HIV genetic polymorphisms and subtype differences on the occurrence of resistance to antiretroviral drugs. Mol Biol Int 2012:256982

    Article  PubMed Central  PubMed  Google Scholar 

  34. Hemelaar J, Gouws E, Ghys PD, Osmanov S (2011) Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25:679–689

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the Fondo de Investigaciones Sanitarias (FIS 09/00284). A. H. is supported by FIS and Agencia Laín Entralgo. R. D. is supported through Instituto de Salud Carlos III, grants FIS1101580 and RD12/0017. This study is included in the Subprograma de Inmigración y Salud, CIBERESP (Spain).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. HIV-1 Molecular Epidemiology Laboratory, Microbiology Department, Hospital Ramón y Cajal (IRYCIS) and CIBERESP, Ctra. Colmenar Viejo km. 9.100, 28034, Madrid, Spain

    Gonzalo Yebra & África Holguín

  2. Microbiology Department, Hospital 12 de Octubre (imas12), Madrid, Spain

    Rafael Delgado

  3. HIV Unit, Hospital 12 de Octubre (imas12), Madrid, Spain

    Federico Pulido & Rafael Rubio

  4. Microbiology Department, Hospital Ramón y Cajal (IRYCIS) and CIBERESP, Madrid, Spain

    Juan Carlos Galán

  5. Infectious Diseases Department, Hospital Ramón y Cajal (IRYCIS), Madrid, Spain

    Santiago Moreno

Authors
  1. Gonzalo Yebra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rafael Delgado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Federico Pulido
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rafael Rubio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Juan Carlos Galán
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Santiago Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. África Holguín
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to África Holguín.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yebra, G., Delgado, R., Pulido, F. et al. Different trends of transmitted HIV-1 drug resistance in Madrid, Spain, among risk groups in the last decade. Arch Virol 159, 1079–1087 (2014). https://doi.org/10.1007/s00705-013-1933-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00705-013-1933-y

Keywords

search

Navigation